Introduction
Bulgaria is a country with low human immunodeficiency virus (hiV) infection prevalence in the general population but there is a risk of rapid spread of epidemics in a certain "most-at-risk" group. For this group there is already epidemiological evidence and the main concern is the possibility of transmission of the infection to the general population (11) .
Official data of the Ministry of Health shows that currently in Bulgaria the number of hiV-positive people registered is 1348. in the course of time the antiretroviral therapy has undergone changes because of drug toxicity, resistance, withdrawal of some medicines (indinavir [IDV] , nelfinavir [nFV] ) and authorization of new medicines. in 2010 the World health organization issued recommendations for shifting stavudine (d4t)-based combination therapies to tenofovir (tDF)-or zidovudine (AZt)-based therapies (10, 14) . these recommendations were set due to clinical evidence of stavudine-related toxicity in long-term treatment. The combination therapy of two or three antivetroviral medicines known as highly active antiretroviral therapy (HAART) remains a standard for hiV-infection treatment. ddi-d4t-SqV-r 300-400 <50 ddi-ABc-SqV-r 300-400 <50 ddi-tDF-SqV-r 300-00 <20 ddi-tDF-SqV-r 300-400 <20
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• patients switched to new therapy in 2009, 2010 and 2011 (retrospectively followed to 2006 and prospectively observed until the end of 2011); • patients who started treatment for the first time with the new medicines in 2010 (prospectively followed to 2011). For the first group we analyzed the changes in the CD4 count and viral load achieved after the therapy switch and its sustainability.
For the second group we analyzed whether the cD4 count and viral load reached stable values in 2011 after starting the HAART therapy.
to evaluate the pharmacotherapy cost we collected information about the medicine prices and calculated the monthly and yearly cost for each HAART dosage regime (9).
Descriptive statistics was applied to evaluate the dynamics in the pharmacotherapy cost, viral load and cD4 count. The statistical significance of the changes of the cost of pharmacotherapy was evaluated by the Wilcoxon and Freedman test by using the median cost for comparison (2) .
to test whether there is correlation between the cost of therapy, viral load, or cD4 count, the Spearman correlation test was applied.
Results and Discussion
In total 162 HIV/AIDS patients were treated in the University infectious Disease clinic. twenty of them were switched to the new medicines in 2009 and followed retrospectively. in 2010 another 8 patients were switched and 20 therapy-naïve patients began HAART, thus reaching a total cohort of 48 patients. Thirty-five of the patients were male and 13, female.
the retrospective analysis for changes in the therapy was applied for 28 patients. nearly 40 different dosage regimes were identified prescribed for all patients and all of them are combinations of 3 or 4 medicines ( Table 1) . Before the introduction of the new medicines in 2006-2009 the therapy was changed for 13 out of 28 observed patients mainly due to lower efficacy or adverse events. Nelfinavir and indinavir were completely removed from all therapeutic combinations. After 2009 all patients were transferred to combinations that include mainly tenofovir, rarely emtricitabine and/or efavirenz, didanozine ( Table 1) .
For the therapy-naive patients tenovofir was prescribed in all 20 cases; efavirenz, in 9 ones; and emtricitabin, in 19 cases ( Table 2) .
the reasons for changes in the antiretroviral therapy in some of patients are due to:
• drug toxicity to some of the medicines in the regimes (stavudine); • resistance to some of the medicines in the regimes (lamivudine); • withdrawal from the pharmaceutical market of some of the medicines in the regimes (nelfinavir, indinavir); • lack of responce to the current therapy;
• authorization of medicines new for the pharmaceutical market with approved efficacy and data for low resistance rates (3). the average monthly cost of the pharmacotherapy increased up to 2010 but then dropped down in 2011 for the therapy-naive patients (Table 3, Fig. 1 ). this shows that the new medicines did not lead to increase in the total expenditures, but, on the contrary, they led to expenditure decrease. Ftc-tDF-eFV 300-400 >1000 200-400 <20
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Ftc-tDF-eFV <100 >1000 >500 <500 (Fig. 1) and the total cost of the yearly therapy of this group increased to 527 169 euro but this increase is associated with better control over the disease.
in 2010 the patients switched to new therapy achieved suppression of the viral load as copies of hiV per milliliter to < 20 and increase of the number of cD4 cells per milliliter > 500 (Table 2, Fig. 2 and Fig. 3) . In 2010 twenty patients were newly registered for HAART treatment. they were with unstable rates of cD4 count and viral load. the annual cost of their therapy was 334 753.2 euro, which increased the total cost of therapy for all patients in 2011 to 861 992.56. During the second year of their therapy the treatment-naive patients reached stable cD4 counts and viral load rates. this might result in savings of further costs for non-pharmacological issues (hospitalizations, treatment with non-antiretrovirals for complications, etc).
The results showed that the patients from the first cohort group (non-treatment-naive) reached sustained stable rates of the cD4 count and the viral load until the end of the observation in 2011, especially during the second year after switching to the new medicines; and this led to decrease in the mean cost of their therapy.
the cost of the therapy did not follow the normal distribution function neither for the average, nor for the mean monthly cost and thus the Wilcoxon test (paired samples) was applied to check the statistical significance in the cost of therapy for the studied years. Statistically significant were the changes in the When we explored the correlation among the therapeutic results and the therapeutic combination used, we found that in 2011 the therapeutic combination used influenced the viral load statistically significantly (p = 0.0064). At the same time it did not change the cost of therapy statistically significantly (p = 0.9497).
our results showed that the treatment of hiV/AiDS patients in Bulgaria follows the contemporary changes and recommendations (15) . As a first HIV/AIDS cost of pharmacotherapy analysis we found that new medicines improve the therapy result without significant changes in the cost (1, 3, 8 ). Thus our results confirm the study questions stated in the beginning of the analysis.
We also confirmed the results that HIV/AIDS is a costly disease, especially in the countries with low health care budgets (12, 13) . on the other hand, our study provides additional evidence that the new HAART therapy improves the disease control and thus hiV/AiDS becomes more of a chronic disease than a deadly infection (5, 7) .
on the basis of the promising results shown by the patients switched to the new combination, we should expect suppression in the viral load and increase in the cD4 count in these patients as well within the next 1 or 2 years (4).
Conclusions
our combined retrospective and prospective observational real life study on the cost and therapeutic results of hiV-infected patient's therapy in the main University Infectious Disease Clinic in Sofia showed that HIV/AIDS remains a costly disease for the Bulgarian population but new medicines lead to better control of its progress and thus could save further hospital costs.
